AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Patent granted for herpes vaccine; peptide may be used as adjuvant for vaccines.

Vaccine Weekly

| July 02, 2003 | COPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2003 JUL 2 - (NewsRx.com & NewsRx.net) -- Cel-Sci Corp. (CVM) has been issued a new U.S. patent, no. 6,572,860, which further expands the proprietary protection for Cel-Sci's herpes simplex-based therapeutic and preventive vaccines.

The patent describes improved versions of the company's already patented core technology that contains within its sequence several epitopes (small pieces of approximately 8-10 amino acids found within foreign proteins) against which the immune system reacts. The patent also describes the combination of these new peptides with the company's L.E.A.P.S. technology for better delivery and presentation to the immune system.

Dan Zimmerman, senior VP research, cellular immunology of Cel-Sci, and inventor of the technology said, "The L.E.A.P.S. technology allows for the preparation of novel immunotherapeutic agents that can target specific types of immune cells and elicit the most appropriate cellular or humoral responses for that disease. In some of our research related to this patent, we have taken two peptides that have been shown to induce protective immune responses in the Herpes Simplex murine challenge model and improved the antigen by making it more broadly immunogenic."

L.E.A.P.S. is a novel T-cell modulation platform technology that enables Cel-Sci to design and synthesize proprietary immunogens. L.E.A.P.S. compounds consist of a peptide epitope associated with a disease-causing agent linked to a T-cell binding peptide ligand (TCBL). Together they induce the immune system to mount either a cellular (e.g., T-cell), humoral (antibody), or a mixed immune response as a means to treat, control or prevent disease.

Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are ...

Related articles from newspapers, magazines, journals, and more
CEL-SCI Corporation's Herpes Simplex Vaccine Protects Mice Against Herpes...
Press release article from: PR Newswire September 30, 1997 700+ words
...Canada, showing that CEL-SCI's herpes simplex vaccine protects...year. A successful herpes simplex virus vaccine would...recurrent disease. CEL-SCI Corporation...tuberculosis, malaria and herpes simplex. "CEL-SCI press releases...
CEL-SCI Corporation Announces Research Grant for Its Herpes Simplex Vaccine
Press release article from: PR Newswire May 27, 1998 700+ words
...PRNewswire/ -- CEL-SCI CORPORATION...studies with its herpes simplex vaccine. This grant...Immunology, at CEL-SCI Corporation...protection against herpes simplex infectivity in animals...vaccine against herpes simplex infection in humans...vaccine is based upon ...
CEL-SCI Receives Grant From the National Institute of Allergy And Infectious...
Press release article from: PR Newswire October 3, 2000 700+ words
...animal challenge model of herpes simplex. This Phase II grant...support the development of a herpes simplex virus vaccine based on CEL-SCI's patented L...Universities College of Medicine (herpes simplex). CEL-SCI Corporation is a...
CEL-SCI and Northeastern Ohio Universities College of Medicine Present CEL-1000...
Press release article from: PR Newswire April 30, 2003 700+ words
...protection data against herpes simplex virus (HSV...tests utilized CEL-SCI's CEL...treatment with CEL-1000 in a mouse skin herpes simplex virus infection...protection against herpes simplex virus and malaria. CEL-1000 represents...
CEL-SCI Receives New U.S. Patent for Herpes Simplex.
Press release article from: PR Newswire June 3, 2003 700+ words
CEL-SCI CORPORATION has...proprietary protection for CEL-SCI's Herpes Simplex based therapeutic and...immune responses in the Herpes Simplex murine challenge model...technology that enables CEL-SCI to design and synthesize...
Herpes simplex infection during pregnancy.(Disease/Disorder overview)
Clinical Reference Systems January 1, 2006 700+ words
What is herpes simplex infection? Herpes simplex is a viral infection that a baby can get from the mother during birth. If you have an active herpes simplex infection when your baby is born, it can harm the child...
Natural remedies for Herpes simplex.(Herpes simplex)
Magazine article from: Alternative Medicine Review Gaby, Alan R. June 1, 2006 700+ words
Abstract Herpes simplex is a common viral infection of the...maybe useful for treating active Herpes simplex lesions or preventing recurrences...2):93-101) Introduction Herpes simplex virus (HSV) infections of the...
Relapsing disease caused by herpes simplex reactivation is a risk.
Newspaper article from: Virus Weekly April 8, 2003 700+ words
...net) -- Relapsing disease caused by herpes simplex reactivation is a risk. According...case is reported to raise awareness of herpes simplex encephalitis as a persisting brain...brain over a five year period after herpes simplex encephalitis." "In addition to a...
For more facts and information, see all results

Source: HighBeam Research, Patent granted for herpes vaccine; peptide may be used as adjuvant...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA